The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Key topics from the 2022 Tandem Meetings
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, summarizes the key topics from this year’s TCT meeting. Discussions about cellular therapies and the ongoing debate about the use of CAR-T therapy versus autologous transplantation in lymphoma and multiple myeloma, as well as advances in CAR-T therapy were at the heart of the meeting. Managing complications of stem cell transplantation was another major theme this year. Dr Sureda also highlights the efforts in improving education and accessibility to transplantation across the globe. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
